Zimbabwe has rejected a significant US health deal worth $367m (272 million pounds) over five years due to Washington's demand for confidential data.
The decision came to light following a internal memorandum from December was leaked, indicating that President Emmerson Mnangagwa believed the agreement was "skewed".
A government spokesman later stated that the United States was requesting biological samples for research and commercial purposes but was not willing to share the resulting advantages from future medical innovations.
"We must now begin the challenging and unfortunate process of winding down our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had donated more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for continued dialogue to reach a deal suitable to both sides so the nation's vital HIV programme can be sustained.
Wider Background
Zimbabwe's decision comes after a similar situation in Kenya, where a high court suspended a similar health funding agreement after legal challenges were filed about the safety of Kenyans' medical information.
After returning to the presidency last year, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
USAID had managed assistance for the American government, but Trump claimed its spending was "inefficient" and his government was pursuing direct bilateral deals to boost transparency and responsibility.
As per statements, Sixteen African countries have so far agreed to similar health pacts, representing more than $18.3bn of fresh investment.
Details of the Declined Agreement
The funds for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration might have yielded significant advantages for the people of Zimbabwe, particularly the 1.2 million currently on HIV treatment through US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, with no equivalent guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that might be developed from that provided information," his statement read.
"In essence, our country would supply the basic resources for scientific discovery with no certainty that the end products would be accessible to our people if a future disease outbreak emerge."
National Interest and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were upending systems already established through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future pandemics.
"This mechanism is designed to ensure that when a country provides its data, the resulting advantages – including medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to develop them."
These objections over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage further discussions with our American counterparts on how subsequent collaboration could be structured in a way that honours the independence and interests of both nations."
Medical Community Response
Medical experts stated it acknowledged the government's concerns, but recommended that negotiations should continue considering much of the country's HIV programmes relied on external financing.
"If technical issues exist, including those relating to data governance or implementation frameworks, these can often be addressed via detailed discussion and negotiated safeguards," the group commented.
The halted deal underscores the continuing tensions between accepting crucial foreign assistance and safeguarding local interests in an increasingly data-driven world.